The first but not the second thrombospondin type 1 repeat of ADAMTS5 functions as an angiogenesis inhibitor.
Biochem Biophys Res Commun
; 371(2): 215-9, 2008 Jun 27.
Article
en En
| MEDLINE
| ID: mdl-18433719
ABSTRACT
Angiogenesis is critical for tumour growth and metastasis where factors that regulate this process are potential targets for development of anti-cancer drugs. In this study, we show that the first TSR domain of the extracellular matrix protease ADAMTS5, unlike the second TSR, has anti-angiogenic activities where it inhibits endothelial cell tube formation on Matrigel, reduces cell proliferation and attachment, while promoting cell apoptosis and migration, all in a dose-dependent manner. Furthermore, it influences the architecture of endothelial cells by disrupting actin stress fibres and reducing focal adhesions, likely via suppressing RhoA activation. TSR1 of ADAMTS5 is therefore a novel anti-angiogenic peptide and could serve as a prototype for future development into anti-cancer drugs.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Péptidos
/
Inhibidores de la Angiogénesis
/
Células Endoteliales
/
Proteínas ADAM
Límite:
Humans
Idioma:
En
Revista:
Biochem Biophys Res Commun
Año:
2008
Tipo del documento:
Article
País de afiliación:
Singapur